AB4AD is a pioneering research initiative focused on Alzheimer's Disease, led by Dr. Daniel Z. Bar from Tel Aviv University. This project explores the pathogen hypothesis, suggesting that certain common infections, particularly herpes and P. gingivalis, may influence the risk of developing Alzheimer's. The research involves analyzing blood and saliva samples from elderly individuals who do not have dementia and comparing them to samples from Alzheimer's patients and younger individuals. The aim is to identify protective antibodies that may explain why some individuals exposed to these infections remain dementia-free. Rather than solely targeting the traditional aspects of protein aggregation, AB4AD emphasizes understanding the natural antibody profiles in individuals who are resilient to Alzheimer's. This approach provides valuable insights that could lead to innovative protective strategies. The initiative is funded and monitored through the Molecule Catalyst platform, which ensures transparency with visible milestones and promotes community governance through the use of IP Tokens. This structure allows participants to engage actively in the research process and decision-making. Overall, AB4AD aims to contribute significantly to the understanding and prevention of Alzheimer's Disease by leveraging the body's natural defenses, offering hope for future therapeutic developments.